Pharnext (ALPHA.PA) Stock Price & Overview
EPA:ALPHA • FR001400N1P4
Current stock price
The current stock price of ALPHA.PA is 0.0002 EUR. Today ALPHA.PA is up by 100%. In the past month the price decreased by -33.33%. In the past year, price decreased by -100%.
ALPHA.PA Key Statistics
- Market Cap
- 1.19K
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -26,278,826.88
- Dividend Yield
- N/A
ALPHA.PA Stock Performance
ALPHA.PA Stock Chart
ALPHA.PA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ALPHA.PA. When comparing the yearly performance of all stocks, ALPHA.PA is a bad performer in the overall market: 99.98% of all stocks are doing better.
ALPHA.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALPHA.PA. ALPHA.PA may be in some trouble as it scores bad on both profitability and health.
ALPHA.PA Earnings
ALPHA.PA Forecast & Estimates
9 analysts have analysed ALPHA.PA and the average price target is 12750 EUR. This implies a price increase of 6374999900% is expected in the next year compared to the current price of 0.0002.
For the next year, analysts expect an EPS growth of 99.81% and a revenue growth -22.9% for ALPHA.PA
ALPHA.PA Groups
Sector & Classification
ALPHA.PA Financial Highlights
Over the last trailing twelve months ALPHA.PA reported a non-GAAP Earnings per Share(EPS) of -26278826.88. The EPS increased by 99.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -627.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALPHA.PA Ownership
ALPHA.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 24.58 | 36.709B | ||
| 1AE | ARGENX SE | 24.39 | 36.66B | ||
| 22UA | BIONTECH SE-ADR | N/A | 18.419B | ||
| 2X1 | ABIVAX SA | N/A | 8.413B | ||
| ABVX | ABIVAX SA | N/A | 8.382B | ||
| GLPG | GALAPAGOS NV | N/A | 1.849B | ||
| GXE | GALAPAGOS NV | N/A | 1.849B | ||
| NANO | NANOBIOTIX | N/A | 1.326B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| IVA | INVENTIVA SA | N/A | 1.073B | ||
| PHIL | PHILOGEN SPA | 18.57 | 672.52M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 871.08 | 455.276M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALPHA.PA
Company Profile
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
Company Info
IPO: 2016-07-18
Pharnext
14 rue de la Republique
Suresnes ILE-DE-FRANCE FR
Employees: 0
Phone: 33141092230
Pharnext / ALPHA.PA FAQ
What does Pharnext do?
Pharnext SA develops and manufactures drugs for neurological diseases. The company is headquartered in Suresnes, Ile-De-France. The company went IPO on 2016-07-18. The firm is focused on discovering, developing and licensing new therapeutic solutions (Pleodrugs) and companion tests for unmet medical needs (large and niche markets) by using the Pleotherapy approach. Pharnext SA runs all its own activities, from research through to clinical development (no further than the end of Phase II trials), and then licenses the Pleodrugs to industrial partners. The firm's prime focus is on neurodegenerative diseases and metabolic diseases.
What is the stock price of Pharnext today?
The current stock price of ALPHA.PA is 0.0002 EUR. The price increased by 100% in the last trading session.
Does ALPHA stock pay dividends?
ALPHA.PA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ALPHA stock?
ALPHA.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of Pharnext (ALPHA.PA)?
Pharnext (ALPHA.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-26278826.88).
What is the market capitalization of ALPHA stock?
Pharnext (ALPHA.PA) has a market capitalization of 1.19K EUR. This makes ALPHA.PA a Nano Cap stock.